Clinical Trial Update: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A safety and efficacy trial update for JCAR017 combinations in relapsed/refractory B-cell malignancies across Phase 1 and Phase 2, completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma Follicular
• Lymphoma Large B-cell Diffuse
• Lymphoma Non-hodgkin

Drugs mentioned

• JCAR017

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-04